Introduction
============

Chronic obstructive pulmonary disease (COPD) is a highly prevalent and progressive respiratory disease.[@b1-copd-10-367] Although mortality for COPD is decreasing in developed countries,[@b2-copd-10-367] it remains a major cause of morbidity and mortality worldwide.[@b1-copd-10-367] Up to 10.2% of adults aged 40--80 years are affected by COPD in Spain,[@b3-copd-10-367] and individuals with COPD experience significant impairment in health-related quality of life (HRQL).[@b4-copd-10-367]

Health utility is a measurement of an individual's preference that shows the value placed on different health states over a specific period. Health utilities are generally measured on a scale of 0--1, with 0 reflecting states of health equivalent to death and 1 reflecting the best possible health status, but sometimes negative values can be obtained, reflecting health states deemed worse than death.[@b5-copd-10-367] Health utilities can help us to understand the impact of diseases on HRQL and are widely used in health economics, as they provide information for clinicians, managers, and other decision-makers on the individual's preferences given to certain health states.[@b6-copd-10-367] Health utilities also allow measuring of the benefits of health interventions in terms of quality-adjusted life years, and are an essential parameter in cost--utility analyses, which are the recommended type of economic evaluation.[@b7-copd-10-367] Another advantage of health utilities is that they allow comparisons between different diseases.[@b5-copd-10-367]

In daily clinical practice, the most common instruments for estimating health utilities are preference-based generic HRQL questionnaires, of which the EuroQol-5D (EQ-5D) is the most widely used.[@b8-copd-10-367] Furthermore, the EQ-5D questionnaire is recommended by health technology assessment bodies like the National Institute for Health and Care Excellence and the Haute Autorité de Santé.[@b6-copd-10-367],[@b9-copd-10-367]

Various international and Spanish studies have estimated utilities in COPD.[@b3-copd-10-367],[@b10-copd-10-367]--[@b18-copd-10-367] However, information on the factors that influence the estimation of utilities in COPD is scarce. Therefore, our objective was to identify the demographic and clinical variables associated with utilities in patients with COPD.

Materials and methods
=====================

This was a multicenter, observational, cross-sectional study including COPD patients recruited between October 2012 and April 2013 from 15 Spanish hospitals with the objective of estimating utilities associated with COPD. More information about study design is detailed in a previous manuscript, wherein we reported utilities stratified by different COPD staging systems.[@b18-copd-10-367] The study was approved by the Clinical Research and Ethics Committee of Hospital Clinic (Barcelona, Spain), and all patients gave written informed consent to participate.

Study population
----------------

Patients of both sexes, aged ≥40 years, with a diagnosis of COPD confirmed by spirometry (post-bronchodilator forced expiratory volume in 1 second \[FEV~1~\]/forced vital capacity \<0.70 and FEV~1~ \<80%) were included. All patients who attended a scheduled outpatient visit and fulfilled the inclusion/exclusion criteria were recruited consecutively by the investigator of each center until the number of patients required had been obtained. In addition, patients had to have been in a stable state for the previous 2 months (no exacerbations, hospitalizations, or changes in treatment), and be current or former smokers. Patients with other respiratory diseases, advanced cancer (with no possibility of remission), terminal patients or those receiving palliative care, and patients with cognitive impairment unable to understand or complete the informed consent form and questionnaires were excluded.

The sample size was determined by the primary objective that was to determine utilities in stable COPD patients stratified by lung function, as described previously.[@b18-copd-10-367]

Data collection and measurements
--------------------------------

The main demographic and clinical variables were collected using a case report form specifically designed for the study. Pre- and post-bronchodilator lung function data were obtained from spirometric testing (last measurement performed in the previous 12 months or, if not available, performed during the inclusion visit).

Comorbidities were evaluated using the Charlson comorbidity index, which predicts 10-year mortality for a patient who may have a range of comorbid conditions.[@b19-copd-10-367] In addition, each patient completed the EQ-5D-3L questionnaire as well as the COPD Assessment Test (CAT)[@b20-copd-10-367] and the modified Medical Research Council Dyspnea Scale (mMRC)[@b21-copd-10-367] to assess patient symptomatology.

EQ-5D-3L is a preference-based generic HRQL questionnaire consisting of five dimensions relating to health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is divided into three levels of functioning (no problems, some problems, and extreme problems). Respondents are asked to describe their health status by ticking off one level of functioning for each of the five dimensions, generating up to 243 different health states. The questionnaire also includes a visual analog scale in which respondents are asked to value their overall health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).[@b8-copd-10-367]

CAT is a COPD-specific questionnaire that measures the impact of the disease on HRQL and allows symptoms to be described. It evaluates the following symptoms: ongoing cough, breathlessness, wheezing, chest tightness, impairment in daily activities, confidence, quality of sleep, and energy. CAT scores range from 0 to 40, with 0 representing the lowest impact on HRQL and 40 the maximum impact.[@b20-copd-10-367]

mMRC measures the impact of dyspnea on the activities of daily living. The score ranges from 0 (no dyspnea) to 4 (dyspnea preventing the patient leaving home or which appears with activities such as dressing or undressing).[@b21-copd-10-367]

Statistical analysis
--------------------

In the univariate descriptive analysis, quantitative variables were described using means and standard deviations and medians and interquartile ranges. Categorical variables were described as absolute frequencies and percentages.

Utilities were derived from EQ-5D-3L scores by applying weighted Spanish societal preferences using the following formula:[@b22-copd-10-367] $$\begin{array}{l}
{\text{Utility} = 1 - 0.024 - 0.106 \cdot (\text{Mobility} = 2) - 0.430 \cdot} \\
{\mspace{72mu}(\text{Mobility} = 3) - 0.134 \cdot (\text{Self-care} = 2) - 0.309 \cdot} \\
{\mspace{72mu}(\text{Self-care} = 3) - 0.071 \cdot (\text{Activity} = 2) - 0.195 \cdot} \\
{\mspace{72mu}(\text{Activity} = 3) - 0.089 \cdot (\text{Pain} = 2) - 0.261 \cdot} \\
{\mspace{72mu}(\text{Pain} = 3) - 0.062 \cdot (\text{Anxiety} = 2) - 0.144 \cdot} \\
{\mspace{72mu}(\text{Anxiety} = 3) - 0.291 \cdot (\text{if~at~least~one~3}) + 0.024 \cdot} \\
{\mspace{72mu}(\text{if~all~answers~are~1})} \\
\end{array}$$

To determine the association between demographic and clinical variables and utility, bivariate analyses were made using nonparametric tests (Kruskal--Wallis and Mann--Whitney *U*-tests for categorical variables and Kendall's tau and Spearman's rho for quantitative variables) due to the strong asymmetry of the utility values.[@b11-copd-10-367],[@b12-copd-10-367]

Additionally, to determine the contribution of each of the variables, a multivariate linear regression model with utility values as dependent variable was developed based on the results of the bivariate analyses and on the clinical criterion and interest of each variable. Coding of variables was, in general, established in previous analyses, although some variables were recoded to provide practical information in the clinical context. In the case of categorical variables, the category with the highest representation was used as the reference group to obtain greater precision at baseline level. For each of the candidate variables to be entered in the multivariate model, a univariate linear regression model was fitted in order to compare the raw effects with the adjusted effects obtained in the multivariate regression. The interactions between variables were explored, but, finally, only the main effects were considered, in order to obtain a parsimonious model that was easy to use and interpret.

The model was fitted by stepwise forward regression, adding variables according to the *t*-statistic and the corresponding *P*-value, and establishing the input and output thresholds of variables as 0.05. As recommended by Brazier et al the performance of the final model was evaluated using the mean error, the mean absolute error, the mean absolute percentage error, and the root mean square error (see [Equations S1](#fd2-copd-10-367){ref-type="disp-formula"}--[S4](#fd5-copd-10-367){ref-type="disp-formula"}).[@b23-copd-10-367] These goodness-of-fit indicators were calculated for the entire range of utilities and for intervals in order to evaluate the behavior of the model throughout the range of utilities.

Statistical significance was established as alpha =0.05. The analyses were performed using the R version 3.1.0 statistical package.[@b24-copd-10-367]

Results
=======

A total of 358 patients were recruited, of whom 346 met all the selection criteria and were included in the final analysis. [Table 1](#t1-copd-10-367){ref-type="table"} shows the characteristics of the study population.

The mean utility obtained from EQ-5D-3L was 0.73 (standard deviation =0.29) and the median was 0.81 (interquartile range =0.26). The range of utilities observed was −0.482 to 1 ([Table 1](#t1-copd-10-367){ref-type="table"}), and 22% of patients had a utility value equal to 1 ("ceiling effect"), which was reflected in a strong asymmetry in the distribution of utility values, where 8.1% of patients had a utility lower than 0.2, representing very poor HRQL, and 3.2% had a utility lower than 0, signifying a health status worse than death.

The bivariate analyses found no significant association between utility and age, smoking status, total packs-years, time since diagnosis, body mass index (BMI), the presence of comorbidities, or Charlson index ([Table 2](#t2-copd-10-367){ref-type="table"}). However, a statistically significant association was found between utilities and sex, time since diagnosis, lung function, positive bronchodilator test, history of exacerbations, and CAT and mMRC scores. Utilities were significantly higher in males than in females (median 0.82 versus 0.74, *P*=0.002) and in patients with milder disease (*P*\<0.001), and showed a positive association with lung function (Kendall's tau =0.24, *P*\<0.001, and Spearman's rho =0.34, *P*\<0.001). [Figure 1A](#f1-copd-10-367){ref-type="fig"} shows the box plot of utilities stratified by disease severity and illustrates that utility values decreased as lung function declined (*P*\<0.001; all pairwise comparisons were statistically significant). In addition, utility values were significantly higher in patients with a positive bronchodilator test (median 0.89 versus 0.81, *P*=0.02). Patients without exacerbations had significantly higher utility values than patients with one or more exacerbations in the previous year (median 0.87 versus 0.78, *P*\<0.001). This association was also observed when the utility values of patients with less than two exacerbations and those with two or more were compared (median 0.84 versus 0.74, *P*\<0.001) ([Figure 1B](#f1-copd-10-367){ref-type="fig"}). Utility values were also significantly associated with both CAT (*P*\<0.001) and mMRC (*P*\<0.001) scores, with the lowest utility values in those patients with more symptoms and with more severe dyspnea ([Table 2](#t2-copd-10-367){ref-type="table"}; [Figure 1C and D](#f1-copd-10-367){ref-type="fig"}).

The multivariate analysis included the variables age, sex, smoking status, time since diagnosis, BMI, the most frequent comorbidities, Charlson index, lung function measured as FEV~1~ predicted post-bronchodilator (continuous), positive bronchodilator test, number of exacerbations, and mMRC score. The CAT score was not included in the multivariate analysis, due to the fact that this is a questionnaire designed to measure the impact of COPD on a patient's life and due to its correlation with the EQ-5D questionnaire.

The final fitted linear regression model included sex, the number of exacerbations, and mMRC score ([Table 3](#t3-copd-10-367){ref-type="table"}), and it explained approximately 38% of the variability in utility values (*R*^2^=0.384). Of the variables included, the mMRC score had the greatest influence on the adjusted utilities in the model. The expression of the final fitted multivariate linear model detailing the calculation of the utility values adjusted by the model is shown (see [Equation S5](#fd6-copd-10-367){ref-type="disp-formula"}). The mean error was −1.1·10^−18^, ranging from −0.4169 for utilities below 0.5 to 0.0704 for utilities above 0.5. The mean absolute error was 0.1649, being 0.4333 for utilities below 0.5 and 0.1195 for utilities above 0.5. The overall root mean square error was 0.2294, being 0.4811 and 0.1497 for utilities below and above 0.5, respectively.

Comparison of the adjusted effects (obtained in the multivariate model) with the raw effects (observed in the univariate models) showed that the difference in utilities between males and females (raw effect =−0.147 \[95% CI: −0.233, −0.060\]) was reduced when the other factors were included in the multivariate linear model (adjusted effect =−0.084 \[−0.154, −0.013\]). The magnitude of the effect associated with the number of exacerbations was also reduced (raw effect =−0.067 \[−0.086, −0.048\], adjusted affect =−0.027 \[−0.044, −0.010\]). Nevertheless, the effects of dyspnea measured with the mMRC score remained about the same ([Table 3](#t3-copd-10-367){ref-type="table"}).

Discussion
==========

This study assessed HRQL, measured in terms of utility, in patients with stable COPD, and studied the relationship between the main demographic and clinical characteristics and utility values in order to show the impact of the disease and its main features on the self-perceived health status of patients.

The mean utility value obtained was 0.73, similar to the 0.69 obtained in a previous large study of 4,574 Spanish COPD patients,[@b15-copd-10-367] but showed a significant reduction of 0.14 (*P*\<0.001) compared to values for the current Spanish population of the same age range.[@b25-copd-10-367] In a Spanish epidemiological population-based study, patients identified as having COPD had a mean utility value of 0.86, which rose to 0.90 in patients without a previous diagnosis of COPD, exactly the same value as control subjects from 40 to 80 years, but was reduced to 0.77 in patients with a previous diagnosis of COPD.[@b3-copd-10-367] These values are also similar to those reported in international studies such as the Understanding the Potential Long-term Impacts on Function with Tiotropium trial (UPLIFT), wherein the mean utility value was 0.76, with significantly lower values in patients with more severe airflow limitation (from 0.79 in stage II to 0.65 in stage IV \[Global initiative for chronic Obstructive Lung Disease stages\]).[@b12-copd-10-367] While most studies have found a weak relationship between low FEV~1~ and impaired HRQL,[@b25-copd-10-367],[@b26-copd-10-367] studies specifically designed to evaluate the association between utility values and FEV~1~ found a statistically significant association.[@b11-copd-10-367],[@b12-copd-10-367] We also observed lower utility values in more severe patients in previously published research,[@b18-copd-10-367] but impairment in FEV~1~ did not remain as a predictor of impairment in utilities when other health determinant factors were taken into account in the multivariate analysis.

Variables significantly associated with utility scores in the multivariate analysis were sex, history of exacerbations in the previous 12 months, and the level of dyspnea. Worse utility values were found in females, as previously described in both the general population and in COPD patients.[@b16-copd-10-367],[@b25-copd-10-367],[@b27-copd-10-367]--[@b29-copd-10-367] The utility values observed were 0.82 for males and 0.74 for females, similar to the 0.78 and 0.69 observed, respectively, in another large Spanish study.[@b16-copd-10-367] Moreover, studies in COPD showed that clinical and physiological variables associated with HRQL, measured by the St George's Respiratory Questionnaire (which is specifically for COPD), also differed between males and females.[@b28-copd-10-367]

Both dyspnea and the history of exacerbations have been reported to be two of the variables with the greatest impact on HRQL in COPD patients. The systematic review by Tsiligianni et al found that the factor that most determined HRQL was dyspnea, which was strongly negatively associated with the health status and had the highest correlations with health status questionnaires.[@b26-copd-10-367] Likewise, studies by Miravitlles et al and Villar et al found a strong association between dyspnea and HRQL.[@b30-copd-10-367],[@b31-copd-10-367] Dyspnea is the starting point of a vicious circle that involves reduced physical activity and a poor health status, and which is linked to poor outcomes, such as an increased risk of hospitalization and mortality.[@b32-copd-10-367],[@b33-copd-10-367] A significant relationship has been found between mean time walked per day by COPD patients and utility scores, increasing from 0.49 in patients walking \<30 minutes per day, to 0.66 in those walking between 30 and 60 minutes and 0.76 for those who walked \>60 minutes per day (*P*\<0.001).[@b34-copd-10-367] In fact, utility scores were one of the three factors significantly associated with physical activity, together with the severity of COPD and the presence of depression.[@b34-copd-10-367]

The history of exacerbations has also been reported to be associated with HRQL,[@b35-copd-10-367]--[@b37-copd-10-367] and has been described as a double effect, with worsening HRQL acting as a marker of the risk of exacerbations and more frequent hospital admissions which, in turn, affect HRQL.[@b36-copd-10-367] In fact, utilities are significantly affected by exacerbations. In a study on 346 patients with an exacerbation of COPD, the mean utility value at the onset of the exacerbation was 0.54, rising to 0.61 at 1-month follow-up.[@b14-copd-10-367] Interestingly, utility values at onset were a marker of the evolution of the exacerbation, with significantly worse scores in those patients who failed the treatment of the exacerbation compared with those who recovered (0.48 versus 0.57, *P*=0.002). Eventually, worse utility values would also identify those patients with a high health care resource utilization.[@b38-copd-10-367]

The multivariate linear model explained 38% of the variability in utility values; this percentage is similar to that found in previous multivariate analyses. Bentsen et al found that the variables analyzed explained 49.6% of the variability in reported HRQL using generic questionnaires and 19.2% when a specific questionnaire was used.[@b39-copd-10-367] The goodness-of-fit indicators of the model show that the model predictions are more accurate for high utility values, ie, for good and/or moderate health states. Even so, the values found are within the range of values from similar models, showing that the model behaves at least as well as similar reported models.[@b23-copd-10-367]

Other variables showed an association with utility scores in the bivariate, but not in the multivariate, analysis. This was the case with low BMI, which was not significant in the multivariate analysis, probably due to the unexpected low number of patients with low BMI in our population. Similarly, another study has found an association between utility values and comorbidities, mainly heart disease and depression.[@b40-copd-10-367] Our results did not show this association, even though patients with cardiovascular disease had a lower utility value than those without, probably due to the lack of power in the hypothesis testing.

A strong association has been found between utilities and CAT scores.[@b41-copd-10-367] Our results confirm the value of the CAT questionnaire in the evaluation of the impact of COPD and justify its exclusion from the variables included in the multivariate analysis, since both scales measure the impact of COPD on a patient's life. Moreover, we wanted to investigate the demographic and clinical characteristics associated with utilities and, therefore, we did not consider the inclusion of another health status questionnaire in the model.

The results of this study are relevant to the understanding of the impact of COPD on HRQL for two main reasons. First, the identification of variables that impact on HRQL may allow the incorporation of changes in the clinical management of patients with stable COPD. Second, utility values are an essential parameter in economic evaluations, specifically in cost--utility analyses in which effectiveness is measured in quality-adjusted life years. Determination of both the utility value and the influence of different variables on it may help build more accurate models for economic evaluation.

Some limitations of the study may have influenced the results. First, in the study design, the sample size calculation was designed for the primary objective of the study that was to estimate the association between utility and lung function impairment. For this reason, the power of the sample to determine other associations may be limited, particularly in the multivariate analysis, in which the impact of several factors was evaluated simultaneously. Second, patients with mild COPD were not included and, therefore, the results cannot be extrapolated to this group of patients. Similarly, in order to obtain utility estimates without the impact on quality of life of current exacerbations, we only included patients who were in a stable state during the previous 2 months. Hence, the results should be interpreted with caution when extrapolated to non-stable COPD patients. Third, the use of generic questionnaires to determine HRQL is controversial, as they may have less discriminative power.[@b42-copd-10-367] While this may be true, the EQ-5D questionnaire was selected as it is recommended for obtaining utility values, with studies supporting its validity in assessing the impact of COPD on HRQL.[@b11-copd-10-367],[@b12-copd-10-367] In addition, patients also completed the specific CAT questionnaire, and there was a moderate-to-strong correlation (Spearman's rho =−0.63 \[*P*\<0.001\], Kendall's tau =-0.48 \[*P*\<0.001\]) between CAT scores and utility values obtained by the EQ-5D questionnaire. Fourth, the study confirmed the so-called ceiling effect, as 22% of patients had the best possible utility value. Although this percentage is consistent with that observed in a previous study,[@b12-copd-10-367] the ceiling effect may limit the validity of the results obtained in the linear regression model. To overcome this potential limitation, the same multivariate analysis was performed using the Tobit and censored least absolute deviations models ([Table S1](#SD1-copd-10-367){ref-type="supplementary-material"}), which take into account the apparent censure in utility values due to the ceiling effect. The three models showed equivalent results (the factors significantly associated with utility values were the same) and, of the three models, linear regression showed the best fit. Finally, 85.5% of the patients enrolled were males. Although this is consistent with the epidemiology of COPD in Spain,[@b3-copd-10-367] the results should be interpreted with caution when extrapolated to females.

Conclusion
==========

This study found that the clinical variables with the greatest influence on HRQL in COPD patients were symptoms such as dyspnea and a history of exacerbations. Lung function, despite being a significant factor in the univariate analysis, lost its significant association with utility values in the multivariate analysis. The estimates obtained from utility values and the impact that the associated variables may have on utility values may allow the incorporation of changes in the clinical management of patients with stable COPD and also could be useful in economic evaluations such as cost--utility analyses.

Supplementary materials
=======================

Calculation of goodness-of-fit indicators
-----------------------------------------

-   Mean error: $${ME} = \frac{1}{n}{\sum_{i = 1}^{n}{y_{i} - {\hat{y}}_{i}}}$$

-   Mean absolute error: $${MAE} = \frac{1}{n}{\sum_{i = 1}^{n}\left| {y_{i} - {\hat{y}}_{i}} \right|}$$

-   Mean absolute percentage error: $${MAPE} = \frac{1}{n}{\sum_{i = 1}^{n}\left| \frac{y_{i} - {\hat{y}}_{i}}{y_{i}} \right|}$$

-   Root mean square error: $${RMSE} = \sqrt{\frac{1}{n}{\sum_{i = 1}^{n}\left( {y_{i} - {\hat{y}}_{i}} \right)^{2}}}$$

    where n is the sample size, y~i~ are the observed values, and ŷ~i~ are the adjusted values.

Utility values adjusted by the proposed linear model
----------------------------------------------------

The utility values adjusted by the proposed linear model were obtained by applying the following formula: $$\begin{array}{l}
{\text{Utility} = 0\text{.89873} + 0\text{.01062} \cdot (\text{mMRC~score} = ``0")} \\
{\mspace{72mu} - 0.12307 \cdot (\text{mMRC~score} = ``2") - 0.23127 \cdot} \\
{\mspace{72mu}(\text{mMRC~score} = ``3") - 0.55889 \cdot (\text{mMRC~}} \\
{\mspace{72mu}\text{score} = ``4") - 0.02701 \cdot (\text{number~of~exacerbations})} \\
{\mspace{72mu} - 0.08361 \cdot (\text{Sex} = ``\text{female}")} \\
\end{array}$$where mMRC is the modified Medical Research Council Dyspnea Scale.

###### 

Multivariate linear, Tobit, and CLAD regressions

  Variable                                Multivariate linear regression   Multivariate Tobit regression   Multivariate CLAD regression                               
  --------------------------------------- -------------------------------- ------------------------------- ------------------------------ ------------------ -------- ---------------------
  Sex (female vs male)                    −0.084                           (−0.154, −0.013)                −0.098                         (−0.182, −0.013)   −0.062   (−0.130, −5·10^−4^)
  Number of exacerbations                 −0.027                           (−0.044, −0.010)                −0.030                         (−0.051, −0.009)   −0.006   (−0.038, 0.0045)
  mMRC score (1 is the reference group)                                                                                                                               
   0                                      0.011                            (−0.088, 0.109)                 0.079                          (−0.053, 0.212)    0.090    (0.0005, 0.113)
   2                                      −0.123                           (−0.185, −0.061)                −0.178                         (−0.253, −0.102)   −0.094   (−0.158, −0.063)
   3                                      −0.231                           (−0.301, −0.161)                −0.298                         (−0.383, −0.213)   −0.222   (−0.297, −0.177)
   4                                      −0.559                           (−0.660, −0.458)                −0.626                         (−0.747, −0.505)   −0.632   (−0.812, −0.341)
  Intercept                               0.899                            (0.855, 0.942)                  0.976                          (0.921, 1.031)     0.910    (0.886, 0.914)

**Note:**

Bias-corrected and accelerated method for CI.

**Abbreviations:** CI, confidence interval; CLAD, censored least absolute deviations; mMRC, modified Medical Research Council.

This study was funded by GlaxoSmithKline (study HZC116842). The authors acknowledge the participation of M Bonnin (H de Figueres, Girona); JA Riesco (H San Pedro de Alcántara, Cáceres); P Casán (Instituto de Silicosis, Oviedo); L Muñoz (H Reina Sofía, Córdoba); JL López-Campos (H Virgen del Rocío, Sevilla); L Comeche (H Quirón, Pozuelo de Alarcón, Madrid); S Alonso (H de Torrejón de Ardoz, Madrid); P García-Sidro (H Universitario de la Plana, Vila-real); JL Viejo (H General Yagüe, Burgos); P Sobradillo (H Txagorritxu, Vitoria); M Valle (H Puerta de Hierro, Madrid) and RM Gómez (H La Princesa, Madrid) for patient recruitment and data collection, and I Pérez for her support and contribution during the design of the study and the review of the manuscript.

**Author contributions**

MM participated in the design of the study and, as lead coordinating investigator, contributed to the analysis and review of the results. AH, together with the GlaxoSmithKline team, developed the idea of the study, and was involved in the design, monitoring of centers, and review of the results. JLLC, MV, and PGS participated as investigators and clinical experts in the development of the protocol and analysis of data. CC and CF were involved in the design of the study and the literature review, and carried out data collection, monitoring of centers, and analysis of the results. All authors contributed to the writing and review of the manuscript and have read and accepted the final version.

**Disclosure**

M Miravitlles has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GlaxoSmithKline, Menarini, Talecris-Grifols, Takeda-Nycomed, and Novartis, and consulting fees from Almirall, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Gebro Pharma, MediImmune, Novartis, Talecris-Grifols, and Takeda-Nycomed. JL López-Campos has received honoraria for lecturing, scientific advice, participating in clinical studies, or writing for publications for (in alphabetical order): Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, Cantabria Pharma, Chiesi, Esteve, Faes, Ferrer, GlaxoSmithKline, Menarini, MSD, Novartis, Pfizer, and Takeda. M Valle has received honoraria for participating in clinical studies, writing for publications, and scientific advice from: Almirall, Astra Zeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GlaxoSmithkline, Menarini, Novartis, Pfizer, and Takeda-Nycomed. P García-Sidro has received fees for scientific meetings, scientific advice, participating in clinical studies, or writing for publications from (in alphabetical order): Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, Gebro, GlaxoSmithKline, Menarini, MSD, Novartis, Pfizer, and Takeda-Nycomed. A Huerta is employed by GlaxoSmithKline, the sponsor of the study. C Forné is employed by Oblikue Consulting, which received financing from GlaxoSmithKline to carry out the study. C Crespo was employed by Oblikue Consulting at the time of the execution and analysis of the study. GlaxoSmithKline did not place any restriction on authors about the statements made in the final paper and the decision to submit was that of the authors alone. The authors report no other conflicts of interest in this work.
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###### 

Characteristics of the study population

  Characteristic                                                       Statistics
  -------------------------------------------------------------------- -----------------
  Age, years, mean (SD)                                                67.9 (9.7)
  Sex, male, n (%)                                                     296 (85.5)
  Current smoker, n (%)                                                68 (19.7)
  Former smoker, n (%)                                                 278 (80.3)
  Pack-years, mean (SD)                                                54.2 (33.2)
  Time from diagnosis, years, mean (SD)                                7.6 (5.8)
  BMI, kg/m^2^, mean (SD)                                              28.0 (5.4)
  Post-bronchodilator lung function, mean (SD)                         
   FVC, mL                                                             2,619.3 (781.8)
   FVC, %                                                              72.5 (18.7)
   FEV~1~, mL                                                          1,272 (506.0)
   FEV~1~, %                                                           46.2 (15.5)
   FEV~1~/FVC, %                                                       48.5 (11.6)
  Positive post-bronchodilator test, n (%)                             41 (15.9)
  Severity of COPD[a](#tfn1-copd-10-367){ref-type="table-fn"}, n (%)   
   GOLD II (moderate)                                                  135 (39.0)
   GOLD III (severe)                                                   145 (41.9)
   GOLD IV (very severe)                                               66 (19.1)
  Comorbidities (the most prevalent), n (%)                            
   Cardiovascular disease[b](#tfn2-copd-10-367){ref-type="table-fn"}   94 (27.1)
   Diabetes                                                            57 (16.4)
   Malignant neoplasias                                                43 (12.4)
  Charlson index, mean (SD)                                            1.0 (1.4)
  At least one exacerbation in the previous year, n (%)                202 (58.4)
  Exacerbations in the previous year, mean (SD)                        1.3 (1.5)
  At least one admission in the previous year, n (%)                   62 (17.9)
  Admissions in the previous year, mean (SD)                           0.3 (0.6)
  Treatment, n (%)                                                     
   Short-acting anticholinergic agents                                 22 (6.4)
   Long-acting anticholinergic agents                                  305 (88.2)
   Short-acting beta-adrenoceptor agonists                             132 (38.2)
   Long-acting beta-adrenoceptor agonists                              321 (92.8)
   Inhaled corticosteroids                                             266 (76.9)
   Theophyllines                                                       21 (6.1)
   Phosphodiesterase IV inhibitors                                     46 (13.3)
   Mucolytics                                                          36 (10.4)
   Leukotriene antagonist                                              4 (1.2)
   Oral corticosteroid                                                 2 (0.6)
   Respiratory rehabilitation                                          42 (12.1)
   Oxygen therapy                                                      93 (26.9)
  CAT total score, mean (SD)                                           16.2 (7.8)
  Impact on CAT impairment, n (%)                                      
   Mild (0--10)                                                        74 (21.4)
   Moderate (10--20)                                                   163 (47.1)
   Severe (20--30)                                                     87 (25.1)
   Very severe (30--40)                                                22 (6.4)
  mMRC total score                                                     1.8 (1.1)
  Dyspnea degree according to mMRC, n (%)                              
   0                                                                   26 (7.5)
   1                                                                   129 (37.3)
   2                                                                   95 (27.5)
   3                                                                   69 (19.9)
   4                                                                   27 (7.8)
  Utility values                                                       
   Mean (SD)                                                           0.73 (0.29)
   Median (IQR)                                                        0.81 (0.26)
   Minimum                                                             −0.482
   Maximum                                                             1

**Notes:**

COPD moderate: FEV~1~/FVC \<0.70 and 50%≤ FEV~1~ \<80%; COPD severe: FEV~1~/FVC \<0.70 and 30%≤ FEV~1~ \<50%; COPD very severe: FEV~1~/FVC \<0.70 and FEV~1~ \<30%.

Cardiovascular diseases are myocardial infarction, congestive heart failure, peripheral vascular disease, and cerebrovascular disease.

**Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; IQR, interquartile range; mMRC, modified Medical Research Council Dyspnea Scale; SD, standard deviation; COPD, chronic obstructive pulmonary disease.

###### 

Bivariate analysis: association between study variables and utility values

  Variable                                                              n (%)        Median (IQR)   *P*-value
  --------------------------------------------------------------------- ------------ -------------- -----------
  Age (years)                                                                                       0.3
   ≤65                                                                  136 (39.3)   0.80 (0.33)    
   \>65                                                                 210 (60.7)   0.81 (0.25)    
  Sex                                                                                               0.002
   Male                                                                 296 (85.5)   0.82 (0.25)    
   Female                                                               50 (14.5)    0.74 (0.44)    
  Smoking status                                                                                    0.9
   Former smokers                                                       278 (80.3)   0.81 (0.25)    
   Current smokers                                                      68 (19.7)    0.81 (0.27)    
  Pack-years                                                                                        0.07
   ≤50                                                                  203 (58.7)   0.82 (0.20)    
   \>50                                                                 143 (41.3)   0.80 (0.30)    
  Time from diagnosis (years)                                                                       0.07
   ≤8                                                                   218 (63.0)   0.82 (0.31)    
   \>8                                                                  128 (37.0)   0.80 (0.25)    
  BMI[a](#tfn4-copd-10-367){ref-type="table-fn"}                                                    0.4
   Underweight                                                          6 (1.7)      0.69 (0.51)    
   Normal                                                               98 (28.3)    0.80 (0.31)    
   Overweight                                                           141 (40.8)   0.82 (0.25)    
   Obese                                                                101 (29.2)   0.81 (0.38)    
  Comorbidities                                                                                     
   Cardiovascular diseases[b](#tfn5-copd-10-367){ref-type="table-fn"}                               
    No                                                                  252 (72.8)   0.82 (0.25)    0.2
    Yes                                                                 94 (27.2)    0.78 (0.30)    
   Diabetes                                                                                         0.8
    No                                                                  289 (83.5)   0.81 (0.25)    
    Yes                                                                 57 (16.5)    0.81 (0.38)    
   Hematological malignancies                                                                       0.8
    No                                                                  303 (87.6)   0.81 (0.27)    
    Yes                                                                 43 (12.4)    0.80 (0.16)    
  Charlson index                                                                                    0.2
   0                                                                    165 (47.7)   0.82 (0.25)    
   1                                                                    77 (22.3)    0.82 (0.40)    
   2                                                                    62 (17.9)    0.74 (0.26)    
   3+                                                                   42 (12.1)    0.81 (0.31)    
  FEV~1~ predicted[c](#tfn6-copd-10-367){ref-type="table-fn"}                                       \<0.001
   Moderate                                                             135 (39.0)   0.87 (0.22)    
   Severe                                                               145 (41.9)   0.80 (0.26)    
   Very severe                                                          66 (19.1)    0.66 (0.42)    
  Positive bronchodilator test                                                                      0.02
   No                                                                   217 (84.1)   0.81 (0.27)    
   Yes                                                                  41 (15.9)    0.89 (0.20)    
  Exacerbations in the previous year                                                                \<0.001
   No                                                                   144 (41.6)   0.87 (0.25)    
   Yes                                                                  202 (58.4)   0.78 (0.31)    
  Exacerbations in the previous year                                                                \<0.001
   \<2                                                                  235 (67.9)   0.84 (0.29)    
   2+                                                                   111 (32.1)   0.74 (0.54)    
  CAT total score                                                                                   \<0.001
   0--10                                                                74 (21.4)    1.00 (0.13)    
   10--20                                                               163 (47.1)   0.84 (0.18)    
   20--30                                                               87 (25.1)    0.65 (0.45)    
   30--40                                                               22 (6.4)     0.28 (0.46)    
  mMRC total score                                                                                  \<0.001
   \<2                                                                  155 (44.8)   0.91 (0.19)    
   2+                                                                   191 (55.2)   0.71 (0.33)    

**Notes:**

Underweight: \<18.5 kg/m^2^; normal: 18.5--25 kg/m^2^; overweight: 25--30 kg/m^2^; and obese: ≥30 kg/m^2^.

Cardiovascular diseases are myocardial infarction, congestive heart failure, peripheral vascular disease, and cerebrovascular disease.

Post-bronchodilator. COPD moderate: FEV~1~/FVC \<0.70 and 50%≤ FEV~1~ \<80%; COPD severe: FEV~1~/FVC \<0.70 and 30%≤ FEV~1~ \<50%; COPD very severe: FEV~1~/FVC \<0.70 and FEV~1~ \<30%.

**Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; mMRC, modified Medical Research Council Dyspnea Scale; COPD, chronic obstructive pulmonary disease.

###### 

Factors associated with utility values in the univariate and multivariate linear regression analyses

  Variable                                                                             Univariate (raw effects)   Multivariate (adjusted effects)                                         
  ------------------------------------------------------------------------------------ -------------------------- --------------------------------- --------- -------- ------------------ ---------
  Age                                                                                  0.001                      (−0.002, 0.004)                   0.6                                   
  Sex (female vs male)                                                                 −0.147                     (−0.233, −0.060)                  \<0.001   −0.084   (−0.154, −0.013)   0.02
  Smoking status (current vs former)                                                   0.001                      (−0.077, 0.079)                   0.9                                   
  Time diagnostic                                                                      −0.005                     (−0.011, 0.0001)                  0.056                                 
  BMI[a](#tfn8-copd-10-367){ref-type="table-fn"} (overweight is the reference group)                                                                                                      
   Underweight                                                                         −0.249                     (−0.487, −0.010)                  0.04                                  
   Normal                                                                              −0.049                     (−0.124, 0.026)                   0.2                                   
   Obese                                                                               −0.019                     (−0.093, 0.056)                   0.6                                   
  Cardiovascular diseases (yes vs no)                                                  −0.041                     (−0.110, 0.029)                   0.3                                   
  Diabetes (yes vs no)                                                                 0.010                      (−0.073, 0.093)                   0.8                                   
  Hematological malignancies (yes vs no)                                               0.031                      (−0.062, 0.125)                   0.5                                   
  Charlson index (0 is the reference group)                                                                                                                                               
   1                                                                                   −0.012                     (−0.091, 0.068)                   0.8                                   
   2                                                                                   −0.041                     (−0.127, 0.045)                   0.3                                   
   3+                                                                                  −0.002                     (−0.102, 0.097)                   0.9                                   
  FEV~1~ (%) predicted post-bronchodilator                                             0.006                      (0.004, 0.008)                    \<0.001                               
  Positive bronchodilator test                                                         0.091                      (−0.007, 0.189)                   0.07                                  
  Number of exacerbations                                                              −0.067                     (−0.086, −0.048)                  \<0.001   −0.027   (−0.044, −0.010)   0.002
  mMRC score (1 is the reference group)                                                                                                                                                   
   0                                                                                   0.034                      (−0.065, 0.134)                   0.5       0.011    (−0.088, 0.109)    0.8
   2                                                                                   −0.135                     (−0.197, −0.072)                  \<0.001   −0.123   (−0.185, −0.061)   \<0.001
   3                                                                                   −0.263                     (−0.332, −0.193)                  \<0.001   −0.231   (−0.301, −0.161)   \<0.001
   4                                                                                   −0.616                     (−0.714, −0.518)                  \<0.001   −0.559   (−0.660, −0.458)   \<0.001

**Notes:**

Underweight: \<18.5 kg/m^2^; normal weight: 18.5--25 kg/m^2^; overweight: 25--30 kg/m^2^; and obese: ≥30 kg/m^2^.

**Abbreviations:** BMI, body mass index; CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council Dyspnea Scale.
